Niagen Bioscience, Inc. — Director's Dealing 2012

Dec 26, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-12-21

Reporting Person: GERMAIN MARK (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-21	Employee Stock Options (right to buy)	$1.50	D	30000	Disposed	2017-12-21	Common Stock (30000)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.50	D	250000	Disposed	2018-04-21	Common Stock (250000)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.545	D	282100	Disposed	2020-05-20	Common Stock (282100)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.545	D	282100	Disposed	2020-05-20	Common Stock (282100)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.545	D	67500	Disposed	2020-05-20	Common Stock (67500)	Direct
2012-12-21	Employee Stock Options (right to buy)	$1.54	D	67500	Disposed	2021-05-10	Common Stock (67500)	Direct
2012-12-21	Employee Stock Options (right to buy)	$0.945	A	586024	Acquired	2022-09-15	Common Stock (586024)	Direct

Footnotes

F1: These previously awarded options have been terminated in exchange of a new award of options under different terms.

F2: Options vested 1/5th every year for 5 years and have been fully vested as of December 21, 2012.

F3: 1/4th of options vested on April 21, 2009 and 1/48th of options vested monthly thereafter. The options have been fully vested as of April 21, 2012.

F4: Options vest 50% over two years beginning on May 20, 2011.

F5: Options vest 50% over two years beginning on May 20, 2011; provided further that, these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certian Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrant have been exercised, then 25% of these options are exercisable; if 50% to 74.9% of such warrant have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable.

F6: Options vested 1/12th every month for 12 months and have been fully vested as of May 20, 2011.

F7: Options vested 1/12th every month for 12 months and have been fully vested as of May 10, 2012.

F8: These new options are awarded by terminating the previously awarded options under different terms.

F9: Options vest 1/12th every month for 12 months and will be fully vested on September 15, 2013.

F10: The total includes 97,500 options under different terms.